D. Boral Capital Reaffirms “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $15.00 price target on the stock. D. Boral Capital’s target price would suggest a potential upside of 146.31% from the company’s previous close.

COYA has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating on shares of Coya Therapeutics in a report on Monday, November 24th. Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Friday, November 14th. Wall Street Zen upgraded shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. Finally, BTIG Research raised their price objective on shares of Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Trading Down 0.8%

COYA opened at $6.09 on Tuesday. The stock has a market capitalization of $127.40 million, a PE ratio of -5.49 and a beta of 0.20. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $8.29. The firm has a 50-day moving average price of $6.21 and a two-hundred day moving average price of $6.05.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. The company had revenue of $3.56 million for the quarter, compared to the consensus estimate of $3.70 million. On average, research analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Trading of Coya Therapeutics

A number of large investors have recently bought and sold shares of the business. CM Management LLC boosted its holdings in shares of Coya Therapeutics by 50.0% in the third quarter. CM Management LLC now owns 300,000 shares of the company’s stock valued at $1,710,000 after buying an additional 100,000 shares during the period. Dauntless Investment Group LLC raised its holdings in shares of Coya Therapeutics by 199.5% during the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after acquiring an additional 101,932 shares during the period. Citadel Advisors LLC lifted its position in Coya Therapeutics by 51.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock valued at $372,000 after acquiring an additional 22,120 shares in the last quarter. Jane Street Group LLC boosted its stake in Coya Therapeutics by 101.7% in the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after purchasing an additional 13,176 shares during the period. Finally, Prosperity Wealth Management Inc. increased its holdings in Coya Therapeutics by 16.4% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after purchasing an additional 3,350 shares in the last quarter. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.